Please assess the completion status of the following clinical trial:

Trial Title: Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject-reported history of dry eye disease in both eyes for at least 6 months;~* History of use of artificial tear eye drops for dry eye symptoms;~* Total score of ≥40 on SANDE;~* TFBUT;~* Corneal fluorescein staining;~* Lissamine green conjunctival staining;~* Schirmer's test score.~Exclusion Criteria:~* Have participated in a previous tavilermide (MIM-D3) study;~* Have clinically significant slit lamp findings at Visit 1;~* Have a history of lacrimal duct obstruction within 12 months of Visit 1;~* Have an uncontrolled systemic disease;~* Be a woman who is pregnant, nursing or planning a pregnancy;~* Be a woman of childbearing potential who is not using an acceptable means of birth control;~* Have a condition or be in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study;~* Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 45 days prior to Visit 1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 1% Tavilermide ophthalmic solution (Type: EXPERIMENTAL): None
- 5% Tavilermide ophthalmic solution (Type: EXPERIMENTAL): None
- Vehicle ophthalmic solution (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).